BackVerona Pharma Plc Overview

Verona Pharma Plc Receivables

Verona Pharma Plc's receivables is $87M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$86.92M

Peer average

Loading

Verona Pharma Plc Receivables History

Loading

Verona Pharma Plc vs. peers: Receivables Comparison

Loading

Verona Pharma Plc Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Verona Pharma Plc (VRNA) FAQ

Verona Pharma Plc (VRNA) currently reports a receivables of $87M as of June 2025. In the prior-year period, the figure was $0. Use the charts on this page to explore Verona Pharma Plc's receivables history and peer comparisons.

Verona Pharma Plc's receivables changed from $0 to $87M (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Verona Pharma Plc reported $87M in receivables as of June 2025. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $87M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Verona Pharma Plc, and consider following VRNA for alerts when major investors trade the stock.

Verona Pharma Plc is classified in the Healthcare sector. On receivables, it currently shows $87M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VRNA with unrelated industries.